Loading organizations...
§ Private Profile · Doylestown, PA, USA
Information about this organization's type, activities, business model, and market focus is currently unknown.
Key people at Celltinel.
Celltinel was founded in 2007 by Amit Bohensky (Founder).
Celltinel is a privately held organization operating in an undisclosed industry, with its specific business activities and corporate headquarters currently remaining unannounced to the public. Detailed financial metrics regarding the company's operational scale, including total funding raised, current market valuation, and exact employee headcount, have not been publicly disclosed in regulatory filings. Furthermore, the enterprise operates without publicly confirming any strategic partnerships, and it has not released the names of any lead institutional investors, venture capital backers, or prominent enterprise customers. The broader strategic focus, target market demographics, and underlying business model of the firm remain entirely confidential, keeping its competitive positioning completely obscured from industry analysts and market researchers. Consequently, the exact founding year and the identities of the original founders responsible for establishing Celltinel remain completely unknown within standard corporate intelligence databases.
Key people at Celltinel.
Celltinel was founded in 2007 by Amit Bohensky (Founder).
Celltheon is a San Francisco Bay Area-based biopharmaceutical company specializing in custom cell line development, complex protein expression, and end-to-end solutions for drug development and manufacturing.[1][3][5] It serves biotech, pharma, and CDMO clients by addressing challenges in producing antibodies and difficult-to-express proteins, offering services like developability optimization, analytical characterization, GLP bioproduction, and scale-up to accelerate clinical timelines.[3][5] With platforms such as OmniCHO™ for rapid transient expression, Goldilocks™ Transposase for high-titer stable cell lines (up to 10–15 g/L), and SUPER CELL™ CHOK1 for biosimilars, Celltheon has supported over 100 global clients on 1000+ proteins with a 100% success rate, enabling gram-scale production in weeks.[3][5]
Founded in 2012 and currently in the Debt/Alive stage with $200K raised, Celltheon demonstrates steady growth through partnerships, such as with Scorpius BioManufacturing, to secure client supply chains and IP while bridging early development to GMP manufacturing.[1][3]
Celltheon was founded in 2012 in Union City, California, as a biotech firm focused on overcoming protein expression hurdles in biotherapeutics development.[1][3][5] While specific founder details are not publicly detailed in available sources, the company's team leverages decades of combined experience in protein expression technologies, evolving from custom services to a comprehensive suite of patented platforms.[3]
Key milestones include developing industry-leading tools like OmniCHO™, Goldilocks™, and SUPER CELL™, which have enabled work on 1000+ proteins for 100+ clients.[3][5] A pivotal partnership with Scorpius highlighted its role in early-stage biotechs, allowing seamless transfer of stable cell lines to GMP facilities and emphasizing responsive, high-quality services for researchers.[1]
Celltheon's strengths lie in its integrated technology platforms and service model, setting it apart in the biopharma CDMO space:
These enable cost reduction, timeline acceleration, and supply chain security via U.S.-based operations and partnerships.[1]
Celltheon rides the wave of biologics and biotherapeutics expansion, where protein expression bottlenecks hinder 70-80% of preclinical programs amid rising demand for complex antibodies, bispecifics, and biosimilars.[3] Its timing aligns with post-pandemic biomanufacturing shortages and a push for resilient, domestic CDMO capacity, as seen in its Scorpius collaboration to de-risk early development for U.S.-based GMP scaling.[1]
Market forces like surging cell/gene therapy needs and regulatory pressures for faster clinical progression favor its platforms, which streamline from discovery to manufacturing.[2][5][6] By serving diverse clients, Celltheon influences the ecosystem through tech transfer, IP protection, and enabling smaller players to compete, ultimately speeding biotherapeutics to patients more affordably.[1][3]
Celltheon is poised for expansion as biopharma demands efficient, high-titer expression for next-gen modalities like ADCs and multi-specifics, potentially scaling via more CDMOs and platform licensing.[3][5][6] Trends in AI-driven protein design and modular manufacturing will amplify its role, with opportunities in cash flow positivity through revenue growth and market share in the $20B+ CDMO space.[1]
Its influence may evolve toward global partnerships and biosimilar dominance, building on a flawless track record to solidify as a go-to for complex biologics—keeping programs moving forward amid industry hurdles.[3]